メチシリン耐性黄色ブドウ球菌（MRSA）の疫学分析、予測（～2033年）

メチシリン耐性黄色ブドウ球菌（MRSA）は病原性の抗生物質耐性菌であり、かなりの罹患率と死亡率を伴います（Vazquez-Sanchezら、2022）。MRSAは感染した環境に応じて、病院や介護施設で発症する医療関連MRSA（HA-MRSA）と市中感染型MRSA（CA-MRSA）に分類されます（CDC、2019）。MRSAは、特に感染しやすい免疫不全患者や高齢患者の増加、侵襲手術の増加、効率的な手洗いや必要のないカテーテルの抜去などの感染対策の不備などの要因により、依然として流行しています（Minnesota Department of Health、2022）。

当レポートでは、主要7市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本）におけるメチシリン耐性黄色ブドウ球菌（MRSA）について調査分析し、MRSAの危険因子、合併症、世界の動向などの情報を提供しています。

目次

第1章 メチシリン耐性黄色ブドウ球菌（MRSA）：エグゼクティブサマリー

• カタリスト
• 関連レポート
• 今後のレポート

第2章 疫学

• 疾患の背景
• 危険因子と合併症
• 世界の過去の動向
• 7MMの予測手法
• MRSAの疫学予測（2023年～2033年）
  • MRSAの入院症例
  • MRSAの入院症例：年齢別
  • MRSAの入院症例：性別
  • MRSAの入院症例：タイプ別
  • MRSAの入院症例：部位A感染タイプ別
  • MRSAの入院症例：部位A感染タイプ別 - 肺炎サブタイプ
  • MRSAの入院症例：部位B感染別
• 議論
  • 疫学予測の考察
  • COVID-19の影響
  • 分析の限界
  • 分析の強み

第3章 付録

List of Tables

• Table 1: Summary of added and removed data types
• Table 2: Summary of updated data types
• Table 3: Risk factors and comorbidities for MRSA

List of Figures

• Figure 1: 7MM, hospitalized incident cases of MRSA, both sexes, N, all ages, 2023 and 2033
• Figure 2: 7MM, hospitalized incidence of MRSA, men and women, cases per 100,000 population, all ages, 2023
• Figure 3: 7MM, sources used to forecast the hospitalized incident cases of MRSA
• Figure 4: 7MM, sources used to forecast the hospitalized incident cases of MRSA by type
• Figure 5: 7MM, sources used and not used to forecast the hospitalized incident cases of site A MRSA infection
• Figure 6: 7MM, sources used to forecast the hospitalized incident cases of MRSA with endocarditis or osteomyelitis
• Figure 7: 7MM, hospitalized incident cases of MRSA, N, both sexes, all ages, 2023
• Figure 8: 7MM, hospitalized incident cases of MRSA by age, N, both sexes, 2023
• Figure 9: 7MM, hospitalized incident cases of MRSA by sex, N, all ages, 2023
• Figure 10: 7MM, hospitalized incident cases of MRSA by type, N, both sexes, all ages, 2023
• Figure 11: 7MM, hospitalized incident cases of MRSA based on site A infection type, N, both sexes, all ages, 2023
• Figure 12: 7MM, hospitalized incident cases of MRSA with pneumonia by subtype, N, both sexes, all ages, 2023
• Figure 13: 7MM, hospitalized incident cases of MRSA with infection B subtype, N, both sexes, all ages, 2023

Methicillin-resistant Staphylococcus aureus (MRSA) is a virulent, antibiotic-resistant bacteria that is associated with considerable morbidity and mortality (Vazquez-Sanchez et al., 2022). MRSA can be categorized according to the setting in which the infection was acquired, as either healthcare-associated MRSA (HA-MRSA), which is acquired in hospitals or in nursing homes, or community-associated MRSA (CA-MRSA) (CDC, 2019). MRSA remains highly prevalent due to several factors, including an increased number of immunocompromised and elderly patients, who are particularly vulnerable to infection, an increase in the number of invasive procedures, and failures in infection control measures, such as efficient handwashing and the removal of non-essential catheters (Minnesota Department of Health, 2022).

Scope

The methicillin-resistant Staphylococcus aureus (MRSA): Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of MRSA in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report includes a 10-year epidemiology forecast for the hospitalized incident cases of MRSA, segmented by sex and age (0-17 years, 18-64 years, and >=65 years). The hospitalized incident cases are further segmented by infection site (site A infections, which consist of pneumonias, skin and soft tissue infections [SSTIs], and bloodstream infections [BSIs], and other infection sites, as well as site B infections, which included endocarditis and osteomyelitis). Additionally, the hospitalized incident cases are segmented by case definition (HA-MRSA and CA-MRSA) in these markets. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast hospitalized incident cases of MRSA across these markets.

Reasons to Buy

The MRSA Epidemiology series will allow you to -

Develop business strategies by understanding the trends shaping and driving the global MRSA markets.

Quantify patient populations in the global MRSA markets to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MRSA therapeutics in each of the markets covered.

Understand magnitude of the MRSA population by age, sex, type, and infection site.

Table of Contents

Table of Contents

• About GlobalData

1 Methicillin-Resistant Staphylococcus aureus (MRSA): Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Forecast assumption and methods: hospitalized incident cases of MRSA
  • 2.4.4 Forecast assumptions and methods: hospitalized incident cases of MRSA by site A infection type
  • 2.4.5 Forecast assumptions and methods: hospitalized incident cases by site B infection type
• 2.5 Epidemiological forecast for MRSA (2023-33)
  • 2.5.1 Hospitalized incident cases of MRSA
  • 2.5.2 Age-specific hospitalized incident cases of MRSA
  • 2.5.3 Sex-specific hospitalized incident cases of MRSA
  • 2.5.4 Hospitalized incident cases of MRSA by type
  • 2.5.5 Hospitalized incident cases of MRSA by site A infection type
  • 2.5.6 Hospitalized incident cases of MRSA by site A infection type - pneumonia subtype
  • 2.5.7 Hospitalized incident cases of MRSA by site B infection type
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the Authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Intelligence and Epidemiology
  • 3.2.1 Global Head of Pharma Research, Analysis and Competitive Intelligence